Sanofi ADR
USUSDSanofi ADR (PA:SAN) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 6. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- sanofi.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Headquarters
- PARIS, France
- CEO
- Paul Hudson
- Employees
- 106 566
- Founded
- 2004
- Listed since
- 03.01.2000 (PA:SAN)
- Shares outstanding
- 1.22 B as of 2025-12-31
- Free float
- 2.16 B
- Market cap
- 98.67 B USD
- Insiders
- 0%
- Institutions
- 8.02%
- Industry (SIC)
- Pharmaceutical Preparations
- Legal form
- QVPB
- ISIN
- FR0000120578
- LEI
- 549300E9PC51EN656011
- P/E
- 22.2
- Payout ratio
- ≈64.0%
- FCF
- 10.8 B EUR
- Payout / FCF
- 47%
- Debt
- 18.7 B EUR1.0 y of FCF
- Dividend streak
- 23 y
- Earnings, FCF and dividends paid — for the 12 months to 31.12.2025 (the company's latest report).
- NAV
Description
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Exchanges and tickers
| Exchange | Ticker | Currency | Price | Type |
|---|---|---|---|---|
| US USA Stocks | SNYNF OTC | USD | 78.17 +1.84% | common stock |
| LSE London Stock Exchange | 0O59 IOB | EUR | 71.63 +0.72% | common stock |
| MI Borsa Italiana (Milan) | 1SAN secondary | EUR | 72.38 +1.26% | common stock |
| PA Euronext Paris | SAN primary | EUR | 72.16 +0.47% | common stock |
| VI Vienna Stock Exchange | SANO secondary | EUR | 71.3 +1.03% | common stock |
| XETRA Xetra | SNW secondary | EUR | 71.78 -1.21% | common stock |
Dividends
Sanofi ADR (SAN) pays dividends once a year. Per year (12 months up to and including the latest announced payment): 4.12 EUR per share (payments: 1). That is about 5.71% of the current share price. Based on payment history, the next ex-dividend date is expected around 04.05.2027. Uninterrupted dividend history: 23 years.
| Ex-date | Payment | Amount | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-07 | 4.1200 EUR | 5.3/5.3 % | annual | PA:SAN |
| 2025-05-12 | 2025-05-14 | 3.9200 EUR | 4.2/4.2 % | annual | PA:SAN |
| 2024-05-13 | 2024-05-15 | 3.7600 EUR | 4.0/7.8 % | annual | PA:SAN |
| 2023-05-30 | — | 3.5600 EUR | 3.6/3.6 % | annual | PA:SAN |
| 2022-05-06 | — | 3.3300 EUR | 3.3/3.3 % | annual | PA:SAN |
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Dodge & Cox Inc. | 10.54% | 28.09 M | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 7.84% | 20.9 M | 2026-06-30 |
| Morgan Stanley | 4.02% | 10.7 M | 2026-06-30 |
| Fisher Asset Management,… | 3.99% | 10.63 M | 2026-06-30 |
| Bank of America Corporat… | 3% | 8.01 M | 2026-06-30 |
| Invesco Ltd. | 2.55% | 6.8 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.47% | 6.57 M | 2026-06-30 |
| Mondrian Investment Part… | 2.07% | 5.52 M | 2026-06-30 |
| Brandes Investment Partn… | 1.55% | 4.14 M | 2026-06-30 |
| AIM Sector Funds (Invesc… | 1.51% | 4.03 M | 2026-04-30 |
| Federated Hermes, Inc. | 1.44% | 3.85 M | 2026-06-30 |
| Boston Partners | 1.44% | 3.84 M | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 15.85 M | 2026-07-31 |
| Putnam ETF Trust-Putnam… | 1.26% | 3.36 M | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 10.53 M | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 8.11 M | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.63% | 1.67 M | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.59% | 1.58 M | 2026-06-30 |
| American Century Capital… | 0.37% | 976 561 | 2026-06-30 |
| Bridge Builder Trust-Bri… | 0.36% | 967 100 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 4.24 M | 2026-07-31 |
| VanEck ETF Trust-VanEck… | 0.35% | 938 561 | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.33% | 4.04 M | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 3.89 M | 2026-08-31 |
| Capital World Growth & I… | 0.3% | 3.67 M | 2026-06-30 |
| -Victory Pioneer Core Eq… | 0.3% | 799 487 | 2026-06-30 |
| Fidelity Covington Trust… | 0.3% | 797 184 | 2026-08-31 |
| NEW PERSPECTIVE FUND | 0.29% | 3.56 M | 2026-06-30 |
| Federated Hermes Eqy. Fd… | 0.29% | 3.48 M | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.29% | 3.44 M | 2026-06-30 |
| Pacer Advisors, Inc. | 0.1% | 1.16 M | 2026-06-30 |
| Generali Investments Cee… | 0% | 29 339 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 19 200 | 2026-06-30 |
| Gamma Investing LLC | 0% | 58 | 2026-06-30 |
| L'Oréal | — | — | — |
